"Proteon Therapeutics to merge with ArTara Therapeutics". www.pharmaceutical-technology.com. 23 September 2019. Retrieved 2020- ... In September 2019, Proteon Therapeutics merged with ArTara Therapeutics. Proteon is developing PRT-201 (vonapanitase), a drug ... Proteon Therapeutics, Inc. is a developer of pharmaceuticals with offices in Waltham, Massachusetts and Kansas City, Missouri. ... "SEC Filings , Proteon Therapeutics Inc". Ir.proteontherapeutics.com. Retrieved 2017-02-28. Lange, Chris (2016-12-13). "Proteon ...

... was a drug development company specialising in the human immune system and new drugs and vaccines to ... "Opsona Therapeutics Limited: Private Company Information - Bloomberg". investing.businessweek.com. Archived from the original ... "Opsona Therapeutics Closes EUR18M Funding - FierceBiotech". www.fiercebiotech.com. Retrieved 27 February 2018. "PR Newswire ... "Emerging finalist: Mark Heffernan Opsona Therapeutics". Retrieved 27 February 2018. Times Higher Educational Supplement - QS ...

"Juno Therapeutics Buys Stage Cell Therapeutics for Up-to-$233M". GEN. 12 May 2015. Staff (May 27, 2015). "Juno, Editas Launch ... Gene therapy "News Release". Juno Therapeutics. Lombardo, Cara (2018-01-22). "Celgene to Buy Juno Therapeutics for $9 Billion ... Juno Therapeutics Inc was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson ... "Juno Therapeutics Acquires X-Body for $44M+". GEN. 2 June 2015. "Celgene Launches $1B Immunotherapy Collaboration with Juno". ...

Official website Business data for PTC Therapeutics, Inc.: Bloomberg Google Reuters SEC filings Yahoo! v t e (CS1 errors: ... 40°33′03″N 74°25′23″W / 40.550722°N 74.423071°W / 40.550722; -74.423071 PTC Therapeutics is a US pharmaceutical company ... cite news}}: ,first= has generic name (help) "In The Spotlight: PTC Therapeutics". NASDAQ.com. 2018-07-23. Retrieved 2018-07-24 ... Bratulic, Anna (2009-09-02). "Roche, PTC Therapeutics to partner on CNS drug discovery - FirstWord Pharma". FirstWord Pharma. ...

... is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware ... "INTARCIA THERAPEUTICS, INC.", AMENDMENT NO. 1 TO FORM S-1, SEC, March 18, 2005, retrieved November 15, 2012 Ron Leuty (November ... "Company Overview of Intarcia Therapeutics, Inc.", Bloomberg Businessweek, archived from the original on January 18, 2013, ...

... was acquired by Merck & Co. in 2006, the cash transaction deal was worth $1.1 billion. Sirna maintained its ... Sirna Therapeutics, Inc. was a San Francisco, California based biotechnology company that explored the use of RNA interference ... "Boulder Campus." Sirna Therapeutics. March 11, 2006. Retrieved on March 3, 2012. San Francisco Bay Area portal Colorado portal ... "Directions." Sirna Therapeutics. March 11, 2006. Retrieved on March 3, 2012. Gordon, Rachel and Bernadette Tansey. "Another ...

... subsidiaries include Lung Biotechnology PBC; Lung Bioengineering Inc.; United Therapeutics Europe, Ltd.; ... "United Therapeutics Converts to a Public Benefit Corporation Following Shareholder Approval". PRNewswire. "United Therapeutics ... United Therapeutics Corp. "Locations." Accessed October 3, 2020. "United Therapeutics Corporation: Company Profile". Dun& ... "Commit To Buy United Therapeutics At $105, Earn 9% Annualized Using Options". Forbes. September 25, 2014. United Therapeutics ...

... is an American biotech company based in Boston, Massachusetts. The company develops novel neuroplasticity- ... "Delix Therapeutics Pursues A Psychedelic-Inspired Medicine Without The Trip". Forbes. Retrieved 2022-05-18. "Harnessing ... "Shire neuro head lands at Delix Therapeutics as CEO". FierceBiotech. 18 March 2021. Retrieved 2021-08-27. Yakowicz, Will. "U.S ... scientificinquirer (2022-03-14). "Industry Matters: Delix Therapeutics is taking Next-Gen psychedelics out of the lab and into ...

"Horizon Therapeutics website: Our Portfolio page". Retrieved 15 May 2020. "Horizon Therapeutics website: Our Portfolio page". ... "Horizon Therapeutics Public Ltd Co 2022 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. 1 March 2023. " ... "Horizon Therapeutics boosts rare-disease portfolio with $3.05 billion Viela buy". Reuters. February 2021. Schere, Dan (6 ... Horizon Pharma Inc (NDAQ:HZNP) agreed to acquire Vidara Therapeutics Inc. in a cash-and-stock deal valued at about $660 million ...

... , Inc. (formerly Samumed, LLC) is a private biopharmaceutical company based in San Diego, California. It ...

"Google Finance Stock Exchange listing for Silence Therapeutics". "About us". silence-therapeutics.com. Archived from the ... therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its ... Silence Therapeutics (Nasdaq: SLN), is a London-based pharmaceutical company formed in 1994. Since its origin, the company has ... Silence Therapeutics develops medicines related to RNA interference or RNAi, to inhibit the expression of specific target genes ...

... is a Waltham, Massachusetts-based biopharmaceutical company developing drugs for neurological disorders ... "2018 NEVYs Nominee Spotlight: Arrakis Therapeutics". New England Venture Capital Association. May 2, 2018. Retrieved July 8, ... a former Biogen executive who co-founded and led Padlock Therapeutics (bought out by Bristol-Myers Squibb in 2016) and ...

Editas Medicine Intellia Therapeutics "CRISPR Therapeutics AG 2022 Annual Report". U.S. Securities and Exchange Commission. 21 ... CRISPR Therapeutics AG is a Swiss-American biotechnology company headquartered in Zug, Switzerland. It was one of the first ... "CRISPR Therapeutics inks deal with Nkarta on gene-edited cell therapies for cancer". The Pharma Letter. 5 July 2021. "CRISPR, ... CRISPR Therapeutics has established partnerships with a number of additional companies such as Viacyte (now part of Vertex), ...

... is a United Kingdom-based biotechnology company formed in 2013 jointly by King's College London, the Wellcome ... The company will focus on development of therapeutics for Alzheimer's disease which target retinoic acid receptor alpha, ... "New U.K. Biotech Firm CoCo Therapeutics Takes on Alzheimer's". Genetic Engineering & Biotechnology News (paper). 1 April 2013. ...

Therapeutics, Sarepta. "Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of ... Sarepta Therapeutics, Inc. (Nasdaq: SRPT) is a medical research and drug development company with corporate offices and ... Renauer, Cory (2019-03-26). "Is Sarepta Therapeutics a Good Gene Therapy Stock to Buy Now? -". The Motley Fool. Retrieved 2019- ... In addition to development of Morpholinos as therapeutics, AVI has conducted six human trials for colorectal and pancreatic ...

... issued a response to the Arizona filing on their website, stating, in part, that "[t]he allegations ... Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona. Its main product was Subsys, a ... A study done by physician and scientist Scott Hadland, examined the marketing of Insys Therapeutics and found that it was ... "Founder and Former Chairman of the Board of Insys Therapeutics Sentenced to 66 Months in Prison". www.justice.gov. January 23, ...

... was a clinical development stage company in the pharmaceutical industry which focused on the treatment of ... "Durata Therapeutics Initiates Phase 3 Study of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure ... "Newly Formed Durata Therapeutics Acquires Pfizer's Vicuron Subsidiary" (Press release). PR Newswire. December 21, 2009. " ...

... 2016. Retrieved September 23, 2018. Corcept Therapeutics Form 10-K for the fiscal year ended December 31 ... Corcept Therapeutics. 2016. Retrieved September 24, 2018. "Corcept Therapeutics Inc (CORT.O)". reuters.com. Reuters. 2018. ... "Corcept Therapeutics Announces Oncology Development Program". corcept.com. Corcept Therapeutics. December 12, 2013. Archived ... Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for ...

... Ltd is a life sciences/pharmaceutical company incorporated in Singapore with primary research facilities and ...

"Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successor - Spark Therapeutics ... "Spark Therapeutics, Inc. 2018 Form 10-K Annual Report". U.S. Securities and Exchange Commission. Higgins, Robert F., and Tina ... Spark Therapeutics, Inc. is a developer of gene therapy treatments, which treat debilitating genetic diseases. It is a ... "Spark Therapeutics: Pioneering Gene Therapy." Harvard Business School Case 818-059, January 2018. Crow, David (19 October 2017 ...

Inc, Flexion Therapeutics (2019-06-20). "Flexion Therapeutics Named one of Boston Business Journal's Best Places to Work for ... Inc, Flexion Therapeutics (2017-10-06). "Flexion Therapeutics Announces FDA Approval of Zilretta™ (triamcinolone acetonide ... Inc, Flexion Therapeutics (2020-04-27). "Flexion Therapeutics Announces Positive Preclinical Data Supporting Development of ... cite web}}: ,last= has generic name (help) Inc, Flexion Therapeutics (2018-11-16). "Flexion Therapeutics Named Top Place to ...

... is a public American pharmaceutical company focused on development of treatments for obesity. The company ...

Scholia has a profile for RNA therapeutics (Q103741648). RNA therapeutics on the rise, Nature (April 2020) (CS1: long volume ... However, mRNA therapeutics do not need to enter into the nucleus to be functional since it will be translated immediately once ... RNA therapeutics are a new class of medications based on ribonucleic acid (RNA). Research has been working on clinical use ... DNA therapeutics needs access to the nucleus to be transcribed into RNA, and its functionality depends on nuclear envelope ...

... Ltd is a clinical stage oncology company. The company is focused on the development of a universal CAR-T ... In August 2022 Prescient announced a manufacturing services agreement with Q-Gen Cell Therapeutics who will produce its OmniCAR ... "Prescient Completes Acquisition of AKTivate Therapeutics" (PDF). asx.com.au. 11 December 2014. Archived (PDF) from the original ... Prescient Therapeutics Ltd (Prescient) was created in 2014 by bringing together two small molecule drug assets from separate US ...

The Therapeutics Initiative was founded in 1994 by the British Columbia Ministry of Health. Since 2013, the organization has ... The Therapeutics Initiative (TI) is an independent organization at the University of British Columbia (UBC) which researches ... They additionally publish the "Therapeutics Letter" and are part of the International Society of Drug Bulletins. In 2008, a ... "Therapeutics Letter". Retrieved 25 December 2015. (University of British Columbia, Pharmacology journals). ...

... , Inc. is a private healthcare company based in Roslyn Heights, New York which specializes in researching and ...

In 2019, Cytori Therapeutics announced that it had changed its focus and name to Plus Therapeutics. In 2020, Plus Therapeutics ... Plus Therapeutics, Inc. was formerly known as Cytori Therapeutics, Inc. In 2017, Cytori Therapeutics announced that it had ... "Pipeline - Plus Therapeutics (PSTV)". Plus Therapeutics. Retrieved 29 May 2022. Official website Business data for Plus ... "Home - Plus Therapeutics (PSTV)". Plus Therapeutics. Retrieved 29 May 2022. "Cytori to Acquire Proprietary Nanoparticle ...

was Insert Therapeutics, Inc. Cerulean Pharma, Inc. IT-101 licensee (Articles with short description, Short description matches ... Insert Therapeutics, Inc., now Calando Pharmaceuticals, Inc., is a medical research company that uses nanobiotechnology ... "Insert Therapeutics, Inc". ctventures.com. Retrieved 1 February 2018. IT-101 trial Calando Pharmaceuticals, Inc. ...

... previously owned Nucynta ER and Nucynta IR. On January 15, 2015, Depomed announced the acquisition of the ... Assertio Therapeutics, Inc. (formerly Depomed, Inc.) is an American specialty pharmaceutical company. It mainly markets ... On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. In 2018, Assertio ... Health care in the United States Cebranopadol Assertio Therapeutics Inc, Bloomberg, retrieved November 20, 2019 "DEPO Income ...

Formerly named Cannasat Therapeutics they changed their name to Cynapsus Therapeutics in 2010. In September 2016, Sunovion (a ... Cynapsus Therapeutics Inc. is a specialty pharmaceutical company developing a drug to treat the motor symptoms of Parkinson's ... subsidiary of Dainippon Sumitomo Pharma) announced it would acquire Cynapsus Therapeutics for approximately $624 million. ...